TY - JOUR
T1 - Loss of Peak Vision in Retinal Vein Occlusion Patients Treated for Macular Edema
AU - Iftikhar, Mustafa
AU - Mir, Tahreem A.
AU - Hafiz, Gulnar
AU - Zimmer-Galler, Ingrid
AU - Scott, Adrienne W.
AU - Solomon, Sharon D.
AU - Sodhi, A.
AU - Wenick, Adam S.
AU - Meyerle, Catherine
AU - Jiramongkolchai, Kim
AU - Liu, T. Y.Alvin
AU - Arevalo, J. Fernando
AU - Singh, Mandeep
AU - Kherani, Saleema
AU - Handa, James T.
AU - Campochiaro, Peter A.
N1 - Funding Information:
Funding/Support: No funding or grant support. Financial Disclosures: Adrienne W. Scott reports personal fees from Allergan Pharmaceuticals and personal fees from Allegro Pharmaceuticals, outside the submitted work. Fernando Arevalo reports personal fees from Turing Pharmaceuticals LLC, personal fees from DORC International B.V. personal fees from Allergan Inc, personal fees from Bayer, personal fees from Mallinckrodt, and grants from TOPCON, outside the submitted work. James T. Handa reports grants from Bayer Pharmaceutical, Inc, outside the submitted work. Peter A. Campochiaro reports grants and personal fees from Aerpio Pharmaceuticals; grants from Alimera Sciences, Inc; grants, personal fees, and other from Allegro; grants and personal fees from Allergan, Inc; personal fees from Applied Genetic Technologies Corporation; grants and personal fees from Asclipix; personal fees from Astellas Pharma, Inc; grants from Clearside Biomedical Inc; personal fees from Exonate Ltd; grants and personal fees from Genentech/Roche Inc; grants from Sanofi; grants, personal fees and other from Graybug Vision; personal fees from Intrexon Corporation; personal fees from Merck & Co, Inc; personal fees from Novartis Pharmaceuticals Corporation; grants from Regeneron Pharmaceuticals, Inc; and grants and personal fees from RXI Pharmaceuticals, outside the submitted work. The following authors have no financial disclosures: Mustafa Iftikhar, Tahreem A. Mir, Gulnar Hafiz, Ingrid Zimmer-Galler, Sharon D. Solomon, Akrit Sodhi, Adam S. Wenick, Catherine Meyerle, Kim Jiramongkolchai, T.Y. Alvin Liu, J. Mandeep Singh, and Saleema Kherani. All authors attest that they meet the current ICMJE criteria for authorship.
Funding Information:
Funding/Support: No funding or grant support. Financial Disclosures: Adrienne W. Scott reports personal fees from Allergan Pharmaceuticals and personal fees from Allegro Pharmaceuticals, outside the submitted work. Fernando Arevalo reports personal fees from Turing Pharmaceuticals LLC, personal fees from DORC International B.V., personal fees from Allergan Inc, personal fees from Bayer , personal fees from Mallinckrodt, and grants from TOPCON, outside the submitted work. James T. Handa reports grants from Bayer Pharmaceutical, Inc, outside the submitted work. Peter A. Campochiaro reports grants and personal fees from Aerpio Pharmaceuticals; grants from Alimera Sciences, Inc; grants, personal fees, and other from Allegro; grants and personal fees from Allergan , Inc; personal fees from Applied Genetic Technologies Corporation; grants and personal fees from Asclipix; personal fees from Astellas Pharma , Inc; grants from Clearside Biomedical Inc; personal fees from Exonate Ltd; grants and personal fees from Genentech / Roche Inc; grants from Sanofi; grants, personal fees and other from Graybug Vision; personal fees from Intrexon Corporation; personal fees from Merck & Co, Inc; personal fees from Novartis Pharmaceuticals Corporation; grants from Regeneron Pharmaceuticals , Inc; and grants and personal fees from RXI Pharmaceuticals, outside the submitted work. The following authors have no financial disclosures: Mustafa Iftikhar, Tahreem A. Mir, Gulnar Hafiz, Ingrid Zimmer-Galler, Sharon D. Solomon, Akrit Sodhi, Adam S. Wenick, Catherine Meyerle, Kim Jiramongkolchai, T.Y. Alvin Liu, J. Mandeep Singh, and Saleema Kherani. All authors attest that they meet the current ICMJE criteria for authorship.
Publisher Copyright:
© 2019 Elsevier Inc.
PY - 2019/9
Y1 - 2019/9
N2 - Purpose: To evaluate long-term visual and anatomic outcomes in patients with retinal vein occlusion (RVO) treated with anti–vascular endothelial growth factor (VEGF) agents. Design: Prospective, interventional case series. Participants: Patients with central RVO (CRVO) or branch RVO (BRVO). Methods: Number of anti-VEGF injections and improvement from baseline best-corrected visual acuity (BCVA) and central subfield thickness (CST) were prospectively recorded in 40 eyes of 39 CRVO patients and 50 eyes of 47 BRVO patients. Results: Mean follow-up was 58 months for BRVO and 78 months for CRVO. Within 6 months of last follow-up, 58% of BRVO patients and 75% of CRVO patients required anti-VEGF injections to control edema. Analysis of the course of each patient over time showed that for BRVO patients, BCVA letter score increased by a mean of 24, from baseline of 52 (20/100) to peak of 76 (20/32), and subsequently decreased by 13, to 63 (20/50), at final visit; and for CRVO patients, BCVA letter score increased by a mean of 26, from baseline of 48 (20/100) to peak of 74 (20/32), and subsequently decreased by 18, to 56 (20/80), at last follow-up. Loss from peak BCVA occurred primarily owing to persistent/recurrent edema and related foveal damage. Conclusions: Patients with RVO showed large improvements in BCVA after initiation of anti-VEGF injections, but in many patients some visual gains were lost over time owing to bouts of recurrent edema. Sustained suppression of VEGF may help to provide optimal outcomes in RVO and reduce treatment burden.
AB - Purpose: To evaluate long-term visual and anatomic outcomes in patients with retinal vein occlusion (RVO) treated with anti–vascular endothelial growth factor (VEGF) agents. Design: Prospective, interventional case series. Participants: Patients with central RVO (CRVO) or branch RVO (BRVO). Methods: Number of anti-VEGF injections and improvement from baseline best-corrected visual acuity (BCVA) and central subfield thickness (CST) were prospectively recorded in 40 eyes of 39 CRVO patients and 50 eyes of 47 BRVO patients. Results: Mean follow-up was 58 months for BRVO and 78 months for CRVO. Within 6 months of last follow-up, 58% of BRVO patients and 75% of CRVO patients required anti-VEGF injections to control edema. Analysis of the course of each patient over time showed that for BRVO patients, BCVA letter score increased by a mean of 24, from baseline of 52 (20/100) to peak of 76 (20/32), and subsequently decreased by 13, to 63 (20/50), at final visit; and for CRVO patients, BCVA letter score increased by a mean of 26, from baseline of 48 (20/100) to peak of 74 (20/32), and subsequently decreased by 18, to 56 (20/80), at last follow-up. Loss from peak BCVA occurred primarily owing to persistent/recurrent edema and related foveal damage. Conclusions: Patients with RVO showed large improvements in BCVA after initiation of anti-VEGF injections, but in many patients some visual gains were lost over time owing to bouts of recurrent edema. Sustained suppression of VEGF may help to provide optimal outcomes in RVO and reduce treatment burden.
UR - http://www.scopus.com/inward/record.url?scp=85068222057&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85068222057&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2019.03.029
DO - 10.1016/j.ajo.2019.03.029
M3 - Article
C2 - 30954469
AN - SCOPUS:85068222057
SN - 0002-9394
VL - 205
SP - 17
EP - 26
JO - American journal of ophthalmology
JF - American journal of ophthalmology
ER -